Patrick Campbell

A new 30,000-person review found low lymphocyte cell counts could be an indicator a patient is at an increased risk of all-cause mortality, including death from cardiovascular disease and cancer.

A discussion on why heart failure rates have climbed over the past decade while research indicates rates of cardiovascular disease, as a whole, have begun to decline.

One-year results of the ENLIGHTEN trial are revealing more about the impact of exercise and nutrition on the cognitive health of older patients.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

Results of the ESETT trial are revealing there is little difference in the effectiveness or safety profiles of three anti-seizure treatments for patients with a severe form epilepsy.

Discussing why initiatives and policy changes in the fight against obesity and diabetes have been perceived as less successful than those against smoking and educating on cardiovascular diseases.

Evaluating the impact of DAPA-HF and other recent data that have changed the way cardiologists view the potential uses of SGLT2 inhibitors in patients with or without diabetes.

Discussing how new information released in 2019 has impacted the way cardiologists view aspirin use for primary and secondary prevention of cardiovascular events.

A new study of more than 100,000 patients in the UK found patients living in areas with greater amounts of air pollution were at an increased risk of glaucoma.

A new study from the University of Minnesota is shedding light on the potentially adverse impact warfarin use can have on bone health compared to DOAC therapies in patients with atrial fibrillation.

Novartis AG is set to acquire The Medicines Company in a $9.7 billion deal that is set to be completed in the first quarter of 2020.

A new analysis from the World Health Organization has found 80% of children across 146 countries, including the United States and Canada, fail to meet the recommended guideline of 1 hour of activity per day.

Results of the CITU study are revealing more about the different impacts e-cigarette and tobacco use has on a patient's lipid profile.

A new analysis from the University of Minnesota has found many patients with and without an indication for regular low dose aspirin use are under or overusing the medication.

A new analysis from Johns Hopkins School of Medicine has found patients in the South, Midwest, and West were all more likely to report poorer healthcare-related quality of life when compared to patients in the Northeast.

A conversation with Deepak Bhatt, MD, MPH, discussing the most impactful advances in cardiology in 2019 and what he sees as the most important advances in the past decade as 2019 comes to a close.

An analysis of 4 phase 3 clinical trials examining the use of bempedoic acid for lowering LDL cholesterol was presented at AHA 2019.

A new study of more than 5000 patients in a rural community in India suggests the Apple Watch and its A-fib software could serve as a valuable screening tool in underserved communities and developing countries.

Seth Bilazarian, MD, medical director of Abiomed, responds to an analysis presented at AHA 2019 suggesting Impella devices were associated with a greater risk of death and stroke.

Results of the "Treat Stroke to Target" trial found an LDL-C target of 70 mg/dL led to a significant reduction in secondary stroke events.

Results of ORION-9 reveal inclisiran has the potential to treat familial hypercholesterolemia with twice-a-year injections.

An analysis of more than 40,000 patients who underwent percutaneous coronary intervention revealed Impella pumps were associated with an increased risk of death, stroke, and kidney injury compared to intra-aortic balloon pumps.

A new study from AHA 2019 has found patients receiving periprocedural colchicine did not decrease their risk of developing PCI-related injuries compared to patients receiving placebo.

Results of the TWILIGHT-ACS study revealed use of ticagrelor plus aspirin following coronary intervention in patients with acute coronary syndrome increased the risk of major bleeding.

A recent analysis of the FRANCE-TAVI registry presented at AHA 2019 has found self-expanding transcatheter heart valves were associated with an increased risk of all-cause mortality following TAVR.

A new study from AHA 2019 has found that use of rivaroxaban rather than antiplatelet therapy after TAVR increased a patient's risk of death and bleeding events.

Results of the ISCHEMIA trial were revealed at AHA 2019 and revealed little overall benefit of an invasive approach but saw improved angina control in patients with previous angina.

The ORION-10 trial revealed 300 mg inclisiran twice-yearly reduced LDL-C levels by 58% in patients with atherosclerotic cardiovascular disease.

Results of the COLCOT trial presented at AHA 2019 revealed colchicine use could reduce the risk of cardiovascular events by 35% in patients who recently suffered a myocardial infarction.

Richard Furie, MD, chief of the division of rheumatology with Norwell Health, discusses the results of a phase 2 trial examining obinutuzumab for lupus nephritis.